Updates on translational and clinical research in systemic sclerosis

Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells

(2023) Christina Bergmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

(2020) Anna-Maria Hoffmann-Vold et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Dinesh Khanna et al.   Lancet Respiratory Medicine

Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease

(2020) Shervin Assassi et al.   Arthritis & Rheumatology

Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis

(2019) Nava Ferdowsi et al.   ANNALS OF THE RHEUMATIC DISEASES

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis

(2019) Elizabeth R. Volkmann et al.   Arthritis & Rheumatology

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease

(2016) M. Kuwana et al.   JOURNAL OF RHEUMATOLOGY